Sanofi’s Dupixent to be reviewed by FDA for moderate-to-severe asthma

This article was originally published here

Sanofi’s supplemental biologics license application of Dupixent (dupilumab) as an add-on maintenance treatment for certain adults and adolescents having moderate-to-severe asthma has been accepted for review by the US Food and Drug Administration (FDA).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply